文献速递银屑病与炎症性皮肤病

中重度斑块状银屑病生物制剂及生物类似药的真实世界安全性、疗效与药物留存率

Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis.
PubMed 文献 · Br J Dermatol · 2018-01-09

基于丹麦DERMBIO登记库2007年1月1日至2017年3月31日的数据,纳入3495个治疗序列(2161例患者),评估阿达木单抗、依那西普、英夫利西单抗、司库奇尤单抗和乌司奴单抗的安全性、疗效与停药时间。乌司奴单抗药物留存率最高,司库奇尤单抗最低但PASI 100应答人数最多;原研药与生物类似药停药风险无显著差异。

要点

  • 乌司奴单抗药物留存率最高,司库奇尤单抗最低。
  • 原研药与生物类似药停药风险无显著差异。
  • 司库奇尤单抗不良事件(以感染为主)最常见。

核心结论

  • 乌司奴单抗与最高的药物留存率相关,司库奇尤单抗与最低的药物留存率相关,尽管司库奇尤单抗多数患者为非初治。
  • 从原研药转换为生物类似药对药物留存率无显著影响,安全性特征相当。

研究设计与样本

  • DERMBIO登记库覆盖所有接受生物制剂治疗的丹麦中重度斑块状银屑病患者。
  • 纳入2007年1月1日至2017年3月31日期间治疗的患者。
  • 采用Kaplan-Meier生存曲线和Cox回归分析药物留存模式。
  • 共纳入3495个治疗序列(2161例患者)。

主要发现

  • 阿达木单抗n=1332;依那西普n=579;英夫利西单抗n=333;乌司奴单抗n=1055;司库奇尤单抗n=196。
  • 司库奇尤单抗PASI 100应答人数最多,但药物留存率在所有生物制剂中最低。
  • 乌司奴单抗总体药物留存率最高。
  • 英夫利西单抗或依那西普的原研药与生物类似药版本之间停药风险无显著差异。
  • 除阿达木单抗和司库奇尤单抗外,所有药物高于批准剂量的治疗均较常见。

临床怎么用

  • 真实世界中乌司奴单抗药物留存率最高,可优先考虑用于需长期维持治疗者。
  • 原研药与生物类似药转换对药物留存无显著影响,安全性相当。
  • 司库奇尤单抗PASI 100应答人数最多但不良事件最常见,需加强感染监测。

局限性

  • 原文未报告具体局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Real-life data on newer biological and biosimilar agents for moderate-to-severe psoriasis are lacking. OBJECTIVES: To examine safety, efficacy and time to discontinuation (drug survival) of biologics (adalimumab, etanercept, infliximab, secukinumab and ustekinumab) and compare originators with biosimilars (i.e. Enbrel with Benepali, and Remicade with Remsima). METHODS: The DERMBIO registry contains data on all Danish patients with moderate-to-severe plaque psoriasis treated with biologics. We examined patients treated between 1 January 2007 and 31 March 2017. We used Kaplan-Meier survival curves and Cox regression to examine drug survival patterns. RESULTS: A total of 3495 treatment series (2161 patients) were included (adalimumab n = 1332; etanercept n = 579; infliximab n = 333; ustekinumab n = 1055 and secukinumab n = 196). Secukinumab had the highest number of PASI 100 (100% improvement from baseline Psoriasis Area and Severity Index) respondents, but also the lowest drug survival among all the biologics. Ustekinumab had the highest drug survival overall. There were no significant differences in discontinuation risk between originator and biosimilar versions of infliximab or etanercept. Treatment with higher than approved dosages was frequent for all drugs except for adalimumab and secukinumab. Adverse events (predominantly infections) were most frequent for secukinumab compared with the other agents. CONCLUSIONS: Ustekinumab was associated with the highest drug survival, and secukinumab with the lowest, although most patients on secukinumab were non-naïve. Switching from originator to biosimilar had no significant impact on drug survival, and the safety profiles were comparable. Adverse events occurred most frequently with secukinumab. Future studies are warranted to assess the long-term safety of novel biologics for psoriasis.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018. PMID: 29094341. doi:10.1111/bjd.16102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。